Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 10, 2026, 11:37 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 978 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Metformin Clear all
Completed Not applicable Interventional Results available

Behavioral Economics and Self-Determination Theory to Change Diabetes Risk (BEST Change)

NCT04902326
View directory record Official record
Conditions
Pre Diabetes
Interventions
Automated educational text messages, Autonomy-supportive automated educational text messages, Financial incentives, Tailored text messages
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
380 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 28, 2024 · Synced Sep 10, 2026, 11:37 PM EDT
Withdrawn No phase listed Observational

Clinical Outcomes and Healthcare Cost and Resource Utilization (HCRU) in Patients With Type 2 Diabetes and Cardiovascular Disease on 2nd Line Empagliflozin Versus 2nd Line Sulfonylureas

NCT05102071
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Cardiovascular Diseases
Interventions
empagliflozin, metformin, sulfonylurea
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Ridgefield, Connecticut
Source: ClinicalTrials.gov public record
Updated May 31, 2022 · Synced Sep 10, 2026, 11:37 PM EDT
Completed Phase 2 Interventional

A Trial of BMS-512148 in Patients With Type 2 Diabetes Mellitus

NCT00263276
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
dapagliflozin, placebo, metformin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 79 Years
Enrollment
389 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
111
States / cities
Bayou La Batre, Alabama • Birmingham, Alabama • Huntsville, Alabama + 107 more
Source: ClinicalTrials.gov public record
Updated Nov 16, 2016 · Synced Sep 10, 2026, 11:37 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of FIAsp in a Basal-bolus Regimen Versus Basal Insulin Therapy, Both in Combination With Metformin in Adult Subjects With Type 2 Diabetes

NCT01850615
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
Faster-acting insulin aspart, basal insulin
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
323 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
32
States / cities
Birmingham, Alabama • Peoria, Arizona • Little Rock, Arkansas + 27 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2019 · Synced Sep 10, 2026, 11:37 PM EDT
Completed Not applicable Interventional Results available

A Pilot Study: Metformin Therapy in Heart Failure Patients With Early Diabetes or at High Risk of Developing Diabetes (Pre-Diabetes)

NCT01573949
View directory record Official record
Conditions
Diabetes, Heart Failure
Interventions
Metformin
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 90 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 3, 2020 · Synced Sep 10, 2026, 11:37 PM EDT
Completed Phase 3 Interventional

Efficacy and Safety of Vildagliptin in Combination With Metformin in Patients With Type 2 Diabetes

NCT00099892
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
vildagliptin
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 78 Years
Enrollment
544 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 1, 2017 · Synced Sep 10, 2026, 11:37 PM EDT
Completed Phase 1 Interventional

Sapanisertib and Metformin in Treating Patients With Advanced or Metastatic Relapsed or Refractory Cancers

NCT03017833
View directory record Official record
Conditions
Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Recurrent Malignant Solid Neoplasm, Refractory Neoplasm
Interventions
Laboratory Biomarker Analysis, Metformin, Pharmacological Study, Sapanisertib
Other · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 3, 2023 · Synced Sep 10, 2026, 11:37 PM EDT
Completed Phase 3 Interventional Results available

A Safety and Efficacy Study of Canagliflozin in Older Patients (55 to 80 Years of Age) With Type 2 Diabetes Mellitus

NCT01106651
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Canagliflozin 100 mg, Canagliflozin 300 mg, Antihyperglycemic agent(s), Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
55 Years to 80 Years
Enrollment
716 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
34
States / cities
Glendale, Arizona • Phoenix, Arizona • Little Rock, Arkansas + 31 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2014 · Synced Sep 10, 2026, 11:37 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Metformin Versus Insulin in Pregnant Women With Type 2 Diabetes

NCT00678080
View directory record Official record
Conditions
Pregnancy Complications
Interventions
Metformin, Insulin (NPH and Regular)
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 52 Years · Female only
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2011
U.S. locations
3
States / cities
Brownsville, Texas • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 27, 2018 · Synced Sep 10, 2026, 11:37 PM EDT
Completed Phase 2 Interventional Results available

Effectiveness of Metformin Compared to Insulin in Pregnant Women With Mild Preexisting or Early Gestational Diabetes

NCT00835861
View directory record Official record
Conditions
Non Insulin Dependent Diabetes, Pregnancy
Interventions
Metformin, Insulin
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older · Female only
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 24, 2017 · Synced Sep 10, 2026, 11:37 PM EDT
Withdrawn Phase 1 Interventional

A Phase 1 Study to Evaluate the Potential Drug Interactions Between Repotrectinib and Metformin, Digoxin, and Rosuvastatin in Patients With Advanced Solid Tumors

NCT05828303
View directory record Official record
Conditions
Advanced Solid Tumor, Metastatic Solid Tumor
Interventions
TPX-0005, Metformin Hydrochloride, Digoxin, Rosuvastatin Calcium
Drug
Lead sponsor
Turning Point Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
2
States / cities
Canton, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 31, 2025 · Synced Sep 10, 2026, 11:37 PM EDT
Terminated Phase 2 Interventional Results available

Metformin as a Chemoprevention Agent in Non-small Cell Lung Cancer

NCT01717482
View directory record Official record
Conditions
Lung Neoplasms, Carcinoma, Non-Small-Cell Lung
Interventions
Metformin, Placebo Comparator
Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 9, 2020 · Synced Sep 10, 2026, 11:37 PM EDT
Completed Phase 2 Interventional Results available

A Study Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK2330672 Administered With Metformin to Type 2 Diabetes Patients

NCT02202161
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
GSK2330672, Placebo, Sitagliptin, Metformin
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
30 Years to 64 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
4
States / cities
Chula Vista, California • Miami, Florida • Baltimore, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2017 · Synced Sep 10, 2026, 11:37 PM EDT
Terminated Phase 4 Interventional Results available

Metformin, Muscle Energetics, and Vascular Function in Older Adults With Peripheral Artery Disease

NCT01901224
View directory record Official record
Conditions
Peripheral Artery Disease
Interventions
Metformin 1000 mg, Placebo
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
40 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 23, 2018 · Synced Sep 10, 2026, 11:37 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Alogliptin Combined With Metformin in Participants With Type 2 Diabetes Mellitus

NCT00286442
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Alogliptin and metformin, Metformin
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 80 Years
Enrollment
527 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
40
States / cities
Phoenix, Arizona • Anaheim, California • Artesia, California + 37 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2012 · Synced Sep 10, 2026, 11:37 PM EDT
Completed Phase 3 Interventional

A Research Study to Determine the Safety and Efficacy of Glucovance Compared to Metformin and Glyburide in Children and Adolescents With Type 2 Diabetes.

NCT00035542
View directory record Official record
Conditions
Diabetes Mellitus, Non-Insulin-Dependent
Interventions
Glucovance (metformin HCl/glyburide), metformin HCl, glyburide
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
9 Years to 16 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
50
States / cities
Birmingham, Alabama • Tucson, Arizona • Beverly Hills, California + 43 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2011 · Synced Sep 10, 2026, 11:37 PM EDT
Completed Phase 2Phase 3 Interventional

A Trial of Metformin in Individuals With Fragile X Syndrome

NCT03479476
View directory record Official record
Conditions
Fragile X Syndrome, Fragile X Mental Retardation Syndrome, Mental Retardation, X Linked, Genetic Diseases, X-Linked, Trinucleotide Repeat Expansion, Fra(X) Syndrome, Intellectual Disability, FXS, Neurobehavioral Manifestations, Sex Chromosome Disorders
Interventions
Placebo Medication, Metformin
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
6 Years to 25 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jan 16, 2025 · Synced Sep 10, 2026, 11:37 PM EDT
Completed Phase 3 Interventional Results available

The Effect of Liraglutide Compared to Sitagliptin, Both in Combination With Metformin on Glycaemic Control in Subjects With Type 2 Diabetes Mellitus

NCT00700817
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
liraglutide, sitagliptin, metformin
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 80 Years
Enrollment
665 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
60
States / cities
Birmingham, Alabama • Escondido, California • Fresno, California + 54 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2017 · Synced Sep 10, 2026, 11:37 PM EDT
Suspended Phase 2 Interventional

Paxalisib With a High Fat, Low Carb Diet and Metformin for Glioblastoma

NCT05183204
View directory record Official record
Conditions
Glioblastoma
Interventions
Paxalisib, Metformin, Ketogenic Diet
Drug · Other
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced Sep 10, 2026, 11:37 PM EDT
Completed Phase 4 Interventional Results available

Sitagliptin in Combination With Metformin and Sulfonylurea

NCT00686634
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Sitagliptin
Drug
Lead sponsor
Charles Drew University of Medicine and Science
Other
Eligibility
18 Years to 75 Years
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 25, 2014 · Synced Sep 10, 2026, 11:37 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of Interaction of Zasocitinib (TAK-279) With Other Medicines in Healthy Adults

NCT06793943
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Zasocitinib, COC, Metformin, Digoxin, Esomeprazole
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 65 Years
Enrollment
78 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Apr 3, 2025 · Synced Sep 10, 2026, 11:37 PM EDT
Completed Phase 3 Interventional Results available

Study of Dapagliflozin in Combination With Metformin XR to Initiate the Treatment of Type 2 Diabetes

NCT00859898
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Dapagliflozin, Metformin XR, dapagliflozin matching Placebo, metformin HCl Modified Release matching Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 77 Years
Enrollment
1,093 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
64
States / cities
Ozark, Alabama • Tempe, Arizona • Concord, California + 53 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2016 · Synced Sep 10, 2026, 11:37 PM EDT
Completed Phase 1 Interventional Results available

A Phase I Study to Assess the Pharmacodynamics of Oral AR-C165395XX in Subjects With Type 2 Diabetes Mellitus (T2DM)

NCT02367066
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
AR-C165395XX, Placebo
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Jun 22, 2016 · Synced Sep 10, 2026, 11:37 PM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Post-Prandial Liver Glucose Metabolism in PCOS

NCT03041129
View directory record Official record
Conditions
Polycystic Ovarian Syndrome, Obesity, Hepatic Steatosis
Interventions
oral glucose tolerance test, MRI of liver
Diagnostic Test
Lead sponsor
University of Colorado, Denver
Other
Eligibility
12 Years to 21 Years · Female only
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 16, 2024 · Synced Sep 10, 2026, 11:37 PM EDT